SELLAS Life Sciences Group, Inc.
SLS
$1.82
-$0.09-4.71%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 12.41M | 11.84M | 13.52M | 13.02M | 13.60M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 28.28M | 29.03M | 32.61M | 32.77M | 34.80M |
| Operating Income | -28.28M | -29.03M | -32.61M | -32.77M | -34.80M |
| Income Before Tax | -26.26M | -27.13M | -30.88M | -32.28M | -34.44M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -26.26 | -27.13 | -30.88 | -32.28 | -34.44 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -26.26M | -27.13M | -30.88M | -32.28M | -34.44M |
| EBIT | -28.28M | -29.03M | -32.61M | -32.77M | -34.80M |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -0.33 | -0.39 | -0.54 | -0.71 | -0.93 |
| Normalized Basic EPS | -0.21 | -0.25 | -0.35 | -0.44 | -0.58 |
| EPS Diluted | -0.33 | -0.39 | -0.54 | -0.71 | -0.93 |
| Normalized Diluted EPS | -0.21 | -0.25 | -0.35 | -0.44 | -0.58 |
| Average Basic Shares Outstanding | 328.56M | 287.63M | 244.69M | 201.50M | 161.60M |
| Average Diluted Shares Outstanding | 328.56M | 287.63M | 244.69M | 201.50M | 161.60M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |